Nomifensine in parkinsonism.

Nomifensine in parkinsonism.

Nomifensine, a tetrahydroisoquinolone antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those identical by levodopa.

Hepatitis induced by nomifensine.

1 Soules MR, McCarty KS. Leiomyomas: steroid receptor content. Am J Obstet Gynecol 1982;143:6-11. 2 Fraser HM. New prospects for luteinising hormone releasing hormone as a contraceptive and therapeutic agent. Br MedJe 1982;285:990-1. 3 Sutherland IA, White S, Chambers GR, et al. A miniature infuser for the pulsatile administration of LHRH. J Biomed Eng 1984;6:129-33. 4 Chong AP, Baggish MS. Man...

Relationships to Nomifensine Bioactivation Mechanisms

Nomifensine: effect in Parkinsonian patients not receiving levodopa.

A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is ...

Identification of Multiple Glutathione Conjugates of Nomifensine in Liver Microsomes and Hepatocyte Preparations: Evidence of the Bioactivation of Nomifensine